Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160472 · ClinicalTrials.gov registry record · NA
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms
A NA study, sponsored by United States Department of Defense.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT00160472: Completed NA study, sponsored by United States Department of Defense.
NCT00160472 is a NA study that has completed, run by United States Department of Defense. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00160472, a NA study, has completed, sponsored by United States Department of Defense.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign (non-cancerous) tissue. The investigators will examine whether AVP protein and AVP and V1 receptor mRNA expression vary with respect to tumor histology, intratumoral vascularization and systemic blood pressure.
Interventions
- PROCEDURE removal of ovarian vessels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2004-03 |
| Est. Completion | 2009-01 |
| Phase | NA |
What the finished NCT00160472 record still lists
NCT00160472 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which removal of ovarian vessels is the first listed.
NCT00160472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00160472 about?
NCT00160472 is a clinical study titled "Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms". This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign (non-cancerous) tissue. The investigators will examine whether AVP protein and AVP...
What is the current status of trial NCT00160472?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2004-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00160472?
The interventions under investigation include: removal of ovarian vessels (PROCEDURE).
Who is sponsoring clinical trial NCT00160472?
This trial is sponsored by United States Department of Defense, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00160472's enrollment target sits among peer trials
110 816th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia